{"id":390058,"date":"2021-04-01T00:00:00","date_gmt":"2021-04-01T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfim0009-2020-biopharma-ulcerative-colitis-disease-landscape-and-forecast-g7-2020\/"},"modified":"2026-04-22T05:22:18","modified_gmt":"2026-04-22T05:22:18","slug":"dlsfim0009-2020-biopharma-ulcerative-colitis-disease-landscape-and-forecast-g7-2020","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfim0009-2020-biopharma-ulcerative-colitis-disease-landscape-and-forecast-g7-2020\/","title":{"rendered":"Ulcerative Colitis | Disease Landscape and Forecast | G7 | 2020"},"content":{"rendered":"<p>The ulcerative colitis (UC) therapy market is expected to grow steadily over the next decade. The entry of first-in-UC oral therapies (e.g., Pfizer\u2019s Xeljanz \/ Xeljanz XR) for moderate to severe disease, together with emerging agents with novel MOAs and a general increase in the use of targeted therapies, will drive market growth. In particular, the availability of non-TNF biologics (e.g., Takeda\u2019s Entyvio, Janssen\u2019s Stelara) and the oral Jak inhibitor Xeljanz \/ Xeljanz XR will expand physicians\u2019 treatment armamentarium and intensify market competition. Offsetting this growth will be the continued generic erosion of conventional agents and the entry of and increased physician comfort prescribing less-expensive biosimilars, factors that will pose hurdles to the uptake of emerging therapies.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul>\n<li>What are the similarities and differences in the treatment of UC by U.S., European, and Japanese gastroenterologists?<\/li>\n<li>How do gastroenterologists perceive biosimilar agents, and what has been\/will be their impact on the UC therapy market?<\/li>\n<li>What are KOLs\u2019 insights into current treatment options (e.g., Pfizer\u2019s Xeljanz \/ Xeljanz XR, Janssen\u2019s Stelara)? What factors drive their treatment decisions?<\/li>\n<li>What are KOLs\u2019 perceptions of key emerging therapies (e.g., AbbVie\u2019s upadacitinib and risankizumab, Janssen&#8217;s guselkumab, Bristol Myers Squibb\u2019s ozanimod, Arena\u2019s etrasimod), and where do they see these agents fitting into the treatment algorithm?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p><em>Disease Landscape &#038; Forecast<\/em> provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n","protected":false},"template":"","class_list":["post-390058","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-ulcerative-colitis","biopharma-date-950"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390058","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390058\/revisions"}],"predecessor-version":[{"id":576426,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390058\/revisions\/576426"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390058"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}